Coherus Oncology, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Coherus Oncology, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Steadiness Ratio: Sales grew in 2 of the last 3 years; profit grew in 3 of 3. Steadier than 85% of Healthcare companies in United States.
- Cash Cushion Ratio: Cash, after subtracting all debt, equals 81% of its market value (net cash). Higher than 85% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
$28For every $100 of sales, $28 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $65 tied up three years earlier.
More money tied up than 60% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
2/3 · 3/3Sales grew in 2 of the last 3 years; profit grew in 3 of 3.
Steadier than 85% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 80%
Sales fell 80% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-80% / -46%In 3 years sales changed by -80% while total assets changed by -46%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-75.8×Operating cash was negative last year, while some debt falls due within a year.
Lower than 79% of Healthcare companies in United States.
Cash Cushion Ratio
+81%Cash, after subtracting all debt, equals 81% of its market value (net cash).
Higher than 85% of Healthcare companies in United States.
Tangible Assets Ratio
82%Of every $100 the company owns, $82 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 52% of Healthcare companies in United States.
Tangible Net Worth Ratio
24%Of every $100 of net worth, $24 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 64% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Coherus Oncology, Inc. made a loss over the last year. Coherus Oncology, Inc. owes $0.68 for every $1 it owns. Net profit rose 489% in the year to Dec 2025.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossCoherus Oncology, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
2.67The share price is 2.67 times Coherus Oncology, Inc.'s book value per share, higher than 52% of Healthcare companies in United States.
Market cap
$162 MThe total market value of all of Coherus Oncology, Inc.'s shares at today's price (share price × number of shares), smaller than 60% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$61 MWhat Coherus Oncology, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.39Net worth divided by the number of shares. The share price of $1.05 is 2.7 times this, which is the P/B above.
Return on equity (ROE)
-178.4%Coherus Oncology, Inc. lost 178.4% of its shareholders' money over the last year, lower than 83% of Healthcare companies in United States.
Owes vs Owns
0.68×Coherus Oncology, Inc. owes $0.68 for every $1 it owns (moderate), higher than 71% of Healthcare companies in United States.
Dividend yield
NoneCoherus Oncology, Inc. does not currently pay a dividend.
Revenue growth
+60%Revenue rose 60% in the year to Dec 2025, and shrank 42% a year on average over 3 years.
Profit growth
+489%Net profit rose 489% in the year to Dec 2025.
Profit margin
398.4%Coherus Oncology, Inc. keeps $398 of every $100 of revenue as net profit.
Cash quality
-0.8×Cash from Coherus Oncology, Inc.'s business was -0.8× its reported profit in the year to Dec 2025 — the business used cash even though it reported a profit.
Interest cover
Not coveredCoherus Oncology, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashCoherus Oncology, Inc. held $132 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Coherus Oncology, Inc.: $162 M ÷ $61 M (30 Jun 2026) = 2.7.
What is Coherus Oncology, Inc.'s return on equity?
Coherus Oncology, Inc. lost 178.4% of its shareholders' money over the last year, lower than 83% of Healthcare companies in United States.
How much does Coherus Oncology, Inc. owe compared with what it owns?
Coherus Oncology, Inc. owes $0.68 for every $1 it owns (moderate), higher than 71% of Healthcare companies in United States.
Does Coherus Oncology, Inc. pay a dividend?
No. Coherus Oncology, Inc. does not currently pay a dividend.
Is Coherus Oncology, Inc.'s revenue growing?
Revenue rose 60% in the year to Dec 2025, and shrank 42% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.